Resilia Pharmaceuticals, Inc. will market and sell Solace™ Eczema Cream, a medical device, as an OTC product in the US, after signing a license agreement with Pelle Ventures, LLC. Financial terms of the transaction were not disclosed. 

Previously only available by prescription, Solace™ Cream is formulated to help control eczema flares and keep future eczema flares dormant longer by utilizing essential skin building blocks like cholesterol, fatty acids, and ceramides to help reduce the likelihood of environmental triggers causing eczema symptoms; as well as employing palmitamide MEA (PEA), a natural endogenous fatty acid to help relieve itchy, dry skin often associated with eczema. 

"We are delighted to add Solace™ Cream to the Resilia portfolio of dermatology products," says Harsha Murthy, Executive Chairman of the Board of Directors at Resilia Pharmaceuticals. "Much is unknown about the causes of eczema, but we do know that eczema has a profound impact on the quality of life in those patients who suffer from its symptoms. Resilia is proud to be able to offer patients an effective and safe product like Solace™ Cream, a product previously available only by prescription. Solace™ Cream fits squarely within Resilia's mission to bring patients high-quality products at reasonable prices." 

Solace™ Cream has been predominately sold on the Amazon® platform. Resilia Pharmaceuticals will begin work immediately to make Solace™ Cream available on Amazon® and plans to expand Amazon promotion. The product had been temporarily unavailable due to COVID-related production challenges.